X0306 4 2019-12-20-07:00 false 0001516551 Emerald Bioscience, Inc. EMBI 0001728413 Emerald Health Sciences Inc. OFFICE 8262 THE LANDING, 200-375 WATER ST. VANCOUVER A1 V6B 0M9 BRITISH COLUMBIA, CANADA false false true false Common Stock 2019-12-20-07:00 4 J false 40800000 4080000 A 126490167 D Warrant(Right to Buy) 0.1 2019-12-20-07:00 4 J false 40800000 0.1 D 2018-01-18-07:00 2023-01-18-07:00 Common Stock 40800000 0 D 7% Convertible Debt 0.4 2019-12-20-07:00 4 J false 4080000 0.4 D Common Stock 10200000 5036250 D On 12/20/2019, the Issuer and the Reporting Person entered into a Warrant Exercise Agreement, pursuant to which the Reporting Person exercised warrants to purchase 40,800,000 shares of Common Stock for an exercise price of $4,080,000. The warrants were issued to the Reporting Person as of 1/18/2018 and 2/16/2018, exercisable over 5 years at $0.10 per share. The exercise price for the warrant shares was paid in the form of a reduction of the corresponding amount of outstanding obligations of the Issuer under the Multi Draw Credit Agreement between the Issuer and the Reporting Person (the "Credit Agreement"), thereby reducing the outstanding principal balance, excluding the debt discount, under the Credit Agreement to $2,014,500. Consists of (i) 113,953,917 shares of Common Stock; (ii) 7,500,000 shares of Common Stock issuable upon exercise of warrants; and (iii) 5,036,250 shares of Common Stock issuable upon conversion of the outstanding principal and accrued interest associated with the Credit Agreement. /s/ Stephen Hall, Chief Financial Officer 2020-01-27-07:00